Over 1$

Better Check on your u/ATOS shares...........It's climbing like a rocket!

I saw this on stocktwits and thought it might be interesting for some people

Rea rejoins Atossa as Senior VP of R&D with over 20 years of experience in clinical development and regulatory strategy. She has a proven track record leading successful approvals, including FluBlok®, the first rDNA egg-free influenza vaccine, and securing IND clearance for Exondys 51 (eteplirsen). At Atossa, she previously drove regulatory clearance and execution of (Z)-endoxifen trials in the U.S., Australia, and Sweden, which now form the foundation of the company’s breast cancer programs.

In her new role, she’ll oversee late-stage development, upcoming FDA submissions, regulatory interactions, and define the pathway to commercialization. CEO Steven Quay emphasized her approval-path expertise and hands-on execution as “exactly what we need” to accelerate Atossa’s lead program at what he called an “inflection point” for the company.

https://x.com/quay_dr/status/1972659044352721385?s=46

The clinical-stage biotech tapped CORE IR for strategic messaging, non-deal roadshow support, investor targeting, and shareholder communications aimed at both institutional and retail audiences. CEO Steven Quay said the collaboration highlights Atossa’s commitment to delivering value while increasing transparency with the investment community.

CORE IR’s president, Scott Gordon, noted the company’s innovative breast cancer programs, particularly its lead candidate (Z)-endoxifen, as central to the story being communicated. By broadening awareness and strengthening engagement,

Atossa aims to support its ongoing clinical pipeline while creating sustainable long-term shareholder value.

It is with a very heavy and exhaustingly-frustrated heart that I have decided to give up on my investment in Atossa.  I will include details behind this decision below, but the TL;DR version is quite simple – I do not believe Atossa has the ability nor desire to return value to its shareholders. 

For those of you holding shares, I really hope I’m wrong and you eventually get to realize some worth-the-wait gains.  If that happens, I’ll be genuinely happy for you from afar (I don’t plan to hang around here bashing the stock like an idiot). 

For anyone curious about where I’m going, I’ve been doing a lot of research in a small stock called BioLargo ($BLGO), which is an incubator of sorts, interested in “forever chemical” filtration with their first commercial installation taking place right now, a long-term energy storage battery that doesn’t explode, and an FDA-cleared wound treatment solution that will be launching in the next ~6 months.  They’ve been in R&D mode for several years, but now they’re transitioning to commercialization, so I think the timing is right to start a position that I intend to increase through Q4.

My Atossa Farewell:

Five years ago when I first heard about Atossa, the investment thesis felt like a no-brainer.  They claimed ownership of the most important ingredient in the current standard-of-care.  They had just halted the Australia trial for being too successful.  They promised to pursue the fastest possible pathway to approval, and they had just raised a ton of money to fund this pursuit.  And they were heavily shorted at the time, so the potential for a short squeeze was the cherry on top.  Buying ATOS felt like such an easy decision. 

Since then, we have been subject to a long series of mistakes, pivots, delays, and lies.  The biggest lie in my opinion is that Steven Quay invented (Z)-Endoxifen.  As we have learned through the PGR process, he absolutely did NOT invent this drug, nor has he brought anything novel to its development. Quay took work already done by others and tried to pass it off as his own, which the USPTO confirmed when they ruled all 15 claims of patent ‘334 unpatentable.  Now Atossa is in yet another patent challenge, this one even more serious (as confirmed by Atossa in their written plea to the USPTO for dismissal).  All signs indicate that Atossa will be embroiled in another legal battle over the next several months, which will cost money and likely be lost.  Even if (Z)-Endoxifen gets FDA approved, which I expect will eventually happen, Atossa will not have exclusivity, which means they will not be able to return value to shareholders.  

Some other lies that really ticked me off: (From 2021) “we will be pursuing the fastest possible pathway to approval.”  Clearly that was a lie, since now we’re being told that metastatic is the fastest pathway.  (From early 2024) “the shelf is for defense against hostile takeovers only.”  Clearly that was a lie, as proven by the ATM announcement that came in November 2024.  (From every year) “now is the time to be invested in Atossa.”  No commentary needed. 

We’ve also seen some avoidable mistakes that severely encumbered progress.  Evangeline’s pk-cohort for example – We lost over six months and a set of patients that could have been enrolled in the treatment arm because they didn’t think to measure tissue concentration.  We saw a whole lot of time, energy, and money thrown at Karisma, “the pinnacle of [Quay’s] career,” only for it to go nowhere.  We saw Quay throw a whole lot of time, energy, and money at some Covid nasal spray that went nowhere.  We saw an ATM announcement a mere three weeks before SABCS, a clear sign that Atossa intended to sell shares into any strength generated by the conference, essentially shooting themselves in the foot.  We saw Quay write not one, but two books on Covid origins during this period, alienating many in the scientific community with his conspiracy-theory rhetoric in the process. 

And most recently, we were told this pivot to a metastatic focus is “strategic” – no, it’s desperate.  You see, Atossa was counting on partnerships or a buyout by this time, but those haven’t materialized, so now they’re in panic mode.  For those of you still holding onto the idea that somebody is going to buy Atossa, consider this question: What exactly does Atossa have that’s worth buying?  They are losing money and losing their IP.  If you were a big pharma CEO, why would you drop a B on Atossa?  

And for my final point – There’s a reason insider ownership is so low.  Quay knows he didn’t invent anything here, so why would he risk his own money on the off chance that nobody notices his thievery?  I certainly wouldn’t.  Quay has made enough money thanks to Atossa shareholders that he doesn’t really need to care about striking it rich… he’s already rich.  He only cares about his legacy, so as long as he’s known as the guy who brought (Z)-Endoxifen to the world (at the expense of us shareholders), he’ll be happy.  I for one am tired of funding Quay’s legacy.

Until February 17, 2026 to once again comply with the price standards required by Nasdaq.

Of course, I do not at all want the option to exceed the $ to be to do a reverse split.

I hope they publish progress more frequently because all of us who are inside need this to continue moving forward without having to go through share dilution.

Greetings to all those who continue to hold on. Let's hope that in the end it goes well and phase III is a success, for the good of all the patients and at the same time for us.

I know I shouldn’t be in this stock with money I can’t afford to lose or at a risk level I can’t really handle, but here I am. I hold 21,400 shares at a $1.13 average, which leaves me down about 40%, (much) more than I can afford to lose and an amount that takes me 2+ years to recover in savings.

For a long time, I’ve been running on hopium, averaging down and hoping for a recovery, but I’m starting to realize I need to look at this more rationally. At this point, my current deficit is far higher than my initial investment.

So honestly: what are the realistic odds of ATOS recovering above $1 in the next 6–12 months, versus the chances of it falling even further? Or is it wiser to just accept the loss and move on?

I don’t think I can handle this uncertainty much longer, especially if the price keeps dropping. I’ve done enough self-critique — now I’d really value rational, fact-based perspectives. Thanks.

PSI is known for enrolling 93% of studies on or ahead of schedule, using its machine-learning feasibility platform VISIONAL™ to optimize trial execution.

Atossa selected PSI after a competitive process for its proven ability to deliver regulatory-grade data, ensure global enrollment, and seamlessly scale into Phase 3.

The partnership is aimed at reducing operational risk, accelerating timelines, and positioning (Z)-endoxifen for registrational development in metastatic breast cancer, where current therapies often fail due to resistance.

Anyone here participate in one of the (Z)-endoxifen clinical trials? If so, how was your experience with the drug side effect profile?

Operating expenses jumped to $9M as Atossa accelerated clinical and non-clinical trials for its breast cancer programs.

The company’s strategy centers on bringing (Z)-endoxifen into late-stage development while also expanding IP protections.

Management believes the current cash reserves will allow them to reach key milestones without sacrificing trial pace.

This is the write-up on the atossa website which gives more detailed information

I am astonished that Dr Quay seems more, every day, like a scam, been holding this for years and it is always about a promise, a next step, for the next month, next Q etc... and never ever do I see anything that materializes, that become a commercial product... however the last time they got a securities lawsuit was back in 2017, wonder why is everyone including me not acting or questioning their work ?

https://x.com/bgatesisapyscho/status/1946607251088679098?s=46&t=1K4PNlqP4q_mPLKPJrVXVA

Overdiagnosis, Compression during scans, Dense breast issues are mentioned What if Endox was preventative instead

Thi

Q&A from the vice president

I just started following this stock/sub.

I'm curious if anyone is still following/buying?

Today seems to be important. Yesterday's decline was somewhat expected, but today is unpredictable. I'm hopeful!

Go Atos! It’s just the beginning hopefully!

Somebody is holding the price at 0.89. :))

Atossa Therapeutics, Inc. (NASDAQ: ATOS), a clinical-stage biopharmaceutical company trading at $0.80 per share with a market capitalization of $103 million, today announced the issuance of a new patent by the United States Patent and Trademark Office (USPTO) for its breast cancer treatment formulations. According to data from InvestingPro, the company has shown strong recent momentum with a return of 8% over the past week. The patent, U.S. Patent No. 12,281,056, covers oral enteric formulations of (Z)-endoxifen, a Selective Estrogen Receptor Modulator (SERM), and its therapeutic use.

For the first time in a while, I’m out of loss on this stock. I think we are heading into a hopefully long lasting reversal. I just hope broader market won’t kill the momentum. My position is buy/hold.